Attached files
| file | filename |
|---|---|
| 10-K - 10-K - Arbutus Biopharma Corp | arbutus10k2019.htm |
| EX-32.1 - EXHIBIT 32.1 - Arbutus Biopharma Corp | exhibit321_soxcertceo2019.htm |
| EX-31.2 - EXHIBIT 31.2 - Arbutus Biopharma Corp | exhibit312_10-kcertcfo2019.htm |
| EX-31.1 - EXHIBIT 31.1 - Arbutus Biopharma Corp | exhibit311_10-kcertceo2019.htm |
| EX-23.2 - EXHIBIT 23.2 - Arbutus Biopharma Corp | exhibit2322019consent.htm |
| EX-23.1 - EXHIBIT 23.1 - Arbutus Biopharma Corp | exhibit231_kpmgconsent2019.htm |
| EX-21.1 - EXHIBIT 21.1 - Arbutus Biopharma Corp | exhibit211_listingofsubsid.htm |
| EX-4.2 - EXHIBIT 4.2 - Arbutus Biopharma Corp | exhibit42descriptionofsecu.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Arbutus Biopharma Corporation (the “Company”) on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I David Hastings, Chief Financial Officer of the Company, certify that to the best of my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company. |
Date: March 5, 2020
/s/ David Hastings | |||
Name: | David Hastings | ||
Title: | Chief Financial Officer | ||